Sonnet BioTherapeutics Holdings Overview

Sonnet BioTherapeutics Holdings Selling, General & Admin

Selling, General & Admin expenses for SONN.

Quarterly SG&A Expenses

$2.80M

↑ 41.81% YoY

As of Sep 30, 2025

Annual SG&A Expenses (TTM)

$8.49M

↑ 38.46% YoY

Trailing 12 months ending Sep 30, 2025

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin